Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.

导出原文传递

翻译打印收藏纠错

作者： Sarah,Oelsner ^[1] ; Anja,Waldmann ^[1] ; Arne,Billmeier ^[1] ; Jasmin,Röder ^[1] ; Aline,Lindner ^[2] ; Evelyn,Ullrich ^[1] ; Rolf,Marschalek ^[3] ; Gianpietro,Dotti ^[4] ; Gundram,Jung ^[5] ; Ludger,Große-Hovest ^[6] ; Pranav,Oberoi ^[7] ; Peter,Bader ^[8] ; Winfried S,Wels ^[9]

作者单位： Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany. ^[1] Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany. ^[2] Division for Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, Goethe University, Frankfurt, Germany. ^[3] LOEWE Center for Cell and Gene Therapy, Goethe University, Frankfurt, Germany. ^[4] Institute of Pharmaceutical Biology, Goethe University, Frankfurt, Germany. ^[5] Lineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC. ^[6] Department of Immunology, Eberhard Karls University, Tübingen, Germany. ^[7] German Cancer Consortium (DKTK), Partner Site Tübingen, Tübingen, Germany. ^[8] German Cancer Research Center (DKFZ), Heidelberg, Germany. ^[9] SYNIMMUNE GmbH, Tübingen, Germany. ^[10] German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany. ^[11]

关键词 B-ALL CD135 FLT3 adoptive immunotherapy chimeric antigen receptor natural killer cells